Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa

@article{Maiza2007LongtermT,
  title={Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa},
  author={Jean Christophe Maiza and Delphine Vezzosi and Maria Pia Matta and Florence Donadille and Florence Loubes-Lacroix and Maxime Cournot and Antoine Bennet and Philippe Caron},
  journal={Clinical Endocrinology},
  year={2007},
  volume={67},
  pages={282 - 289}
}
CONTEXT The role of somatostatin analogues (SSTa) in the treatment of acromegaly. OBJECTIVE To evaluate the antihormonal and antitumour efficacy of long-term (up to 18 years) primary treatment with SSTa in patients with GH-secreting pituitary adenoma responsive to SSTa. DESIGN An open, prospective, single-centre, clinical study. PATIENTS Thirty-six acromegalic patients, aged 17-75 years (postoral glucose tolerance test GH > 1 microg/l, increased IGF-1 for age and sex), were monitored in a… CONTINUE READING
BETA

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 52 CITATIONS

FILTER CITATIONS BY YEAR

2007
2018

CITATION STATISTICS

  • 3 Highly Influenced Citations

  • Averaged 2 Citations per year over the last 3 years

References

Publications referenced by this paper.
SHOWING 1-10 OF 40 REFERENCES

Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GHsecreting pituitary adenomas

  • P. Jaquet, A. Saveanu, +6 authors M. D. Culler
  • 2005

Similar Papers

Loading similar papers…